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1. Introduction 
Recent years have witnessed several gram-negative bacteria (GNB) species and a few gram-
positive bacteria (especially the Staphylococcus aureus) posing overwhelming threats to the 
healthcare-associated infections as a series of frightening superbugs (Engel, 2010; Peleg & 
Hooper, 2010). It is primarily due to the fact that incidence of multidrug resistance (MDR) or 
pan-drug resistance (PDR) bacteria have been escalating in a manner of global dimension, 
frequent prevalence and alarming magnitude. The predominate resistance issues are those 
related to GNB species, including Enterobacteriaceae (Deshpande & et al, 2010), Klebsiella 
pneumonia, Pseudomonas aeruginosa and Acinetobacter baumannii. Theses circulating isolates 
have created big problems for treatment of  nosocomial infection because they carry highly 
transmissible elements encoding multiple resistance genes, e.g. extended-spectrum beta-
lactamases (ESBLs) that inactivates different classes of first-line antibiotics (Bush, 2010; 
Engel, 2010), metallo-beta lactamase that hydrolyzes penicillins, cephalosporins and 
carbapenems, efflux pumps that decrease bacterial transporting ability to almost all 
antibiotics and natural antimicrobial products (Pages & et al, 2010), and promoters that 
ensure the transcription of these genes.   
Traditional antimicrobial drugs target only a few cellular processes and are derived from a 
few distinct chemical classes. Despite that genetic screens to identify new drug targets and 
classic searching for new chemical leads with diverse structures (Moellering, Jr., 2011), the 
constant need of new broad-spectrum antimicrobial agents has rarely been met (Cattoir & 
Daurel, 2010). Meanwhile, antibacterial strategies that favor in offering timely therapeutic 
countermeasures are urgently required for possible outbreaks of new super bug infections. 
One promising strategy is antisense antibacterial, which can contribute to both aspects of the 
problem. It is generally described as RNA silencing in bacteria using synthetic nucleic acid 
oligomer mimetics to specifically inhibit essential gene expression and achieve gene-specific 
antibacterial effects. First proposed in 1991, RNA targeting in bacterial has been made more 
flexible by 20 years of technology refinement, circumventing major problems of target 
selection/validation and efficient delivery (Bai & et al, 2010). Antisense antibacterials have 
been developed by constructing sequence-designed synthetic RNA silencers using new 
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chemical classes, e.g. nucleic acid mimics peptide nucleic acid (PNA) and 
phosphorodiamidate morpholino (PMO), that conjugated with cell penetrating peptide 
(CPP) in multiple functional ways (Geller, 2005; Hatamoto & et al, 2010). And their potent 
bactericidal effects have been displayed in a variety of pathogens by targeting several 
growth essential genes in vitro and in vivo (Bai & et al, 2010). Advantage of RNA silencing is 
unique in having the potential to selectively kill target pathogens with species and even 
strain specificity. Of particular interest are possibilities to tailor the antibacterial spectrum, 
aid the use of conventional antibiotics by potentiating their activity, and reverse resistance. 
Further, antisense antibacteirals may present an unusual opportunity for developing broad-
spectrum therapeutics against upgrading infections caused by multi-drug or pan-drug 
resistant pathogenic  species, where many successful compounds have failed.  This review 
will describe the characteristics of the antisense antibacteiral strategy (including antisense 
mechanism, basic chemistry involved in nucleic acid analogs, their anti-infection 
applications in vitro and in vivo, and preliminary studies on pharmacokinetics and toxicity), 
and focus on the major determinants of target accessibility and CPP-mediated delivery in 
the general context of antisense antibacterials. We will also highlight the promising targets 
and delivery strategies that favor the possible development of broad-spectrum nucleic acid-
based therapeutic molecules and provide overall information of their potentials as 
functional component of systemic broad-spectrum antisense antibacterial agents. 
2. Antisense antibacterials: 20 years of technology refinement 
Antisense antibacterial strategy is revolutionary for silencing essential genes at mRNA level 
by antisense oligodeoxyribonucleotides (AS-ODNs) for realization of bacterial cell death or 
restoration of susceptibility. Significant technology advances in aspects of microbial 
genomics (Monaghan & Barrett, 2006), structural modification of oligonucleotides and 
efficient delivery systems have fundamentally promoted the transformation of antisense 
antibacterials from concept to future therapeutic “antisense antibiotics”. 
2.1 Mechanism of action and chemistry 
AS-ODNs are designed to bind the target mRNA to prevent translation or bind DNA to 
prevent gene transcription respectively. And once bound to the target, AS-ODNs modulate 
its function through a variety of post binding events. Meanwhile, AS-ODNs based on the 
three generations of modified structures, have overcome the biological disadvantages of 
RNA and DNA, and shown great potency in gene expression inhibition with apparently 
high degree of fidelity and exquisite specificity both in vitro and in vivo. 
2.1.1 Antisense mechanism 
Most of the reported work on antisense drugs has been accomplished in eukaryotic systems 
and their mechanisms have been well explored (Houseley & Tollervey, 2009). AS-ODNs 
bind to the target RNA by well-characterized Watson-Crick base pairing mechanism. The 
effect of gene silencing or “knock down” that happens after the binding can be broadly 
categorized as cleavage-dependent or occupancy-only mechanism (Figure 1). Cleavage-
dependent mechanism includes degradation of RNA:mRNA duplexes by double-strand 
RNA (dsRNA)-specific RNAases (a natural means of transcriptional regulation),  
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degradation of stable DNA:RNA heterodimers through the activity of RNAse H, and 
degradation via the action of RNase P (only if external guide sequences are coupled to the 
oligonucleotide). Occupancy-only mechanism, also known as translation arrest, features as 
that AS-ODN:RNA heteroduplexes inhibit translation by steric blocking the ribosomal 
maturation and polypeptide elongation process. Antisense antibacterials function on the 
base of above antisense mechanisms, whereas the specific mechanism is dependent on the 
structural chemistry and design of the modified oligonucleotides (Bennett & Swayze, 2010). 
DNA
(gene)
Messenger RNA
(mRNA)
oligonucleotide
Transcription
Translation
Proteins
Traditional Drug
Diseases
1. Cleavage-dependent mechanism
modified
oligonucleotide
RNase H
Cleavage
Steric Block
30S 
50S 
30S 
50S 
2. Occupy-only  mechanism
RNase P
Cleavage
External guide sequence
oligonucleotide
 
Fig. 1. Different antisense mechanisms: antisense oligodeoxyribonucleotides (AS-ODNs) are 
known to interact and block the function of the mRNA. Different antisense mechanisms 
shown include the nondegradative mechanisms (e.g., inhibition of translation) and 
mechanisms that promote degradation of the RNA (e.g., RNase H mediated cleavage and 
external guided sequence mediated RNase P cleavage). 
2.1.2 Nucleic acid chemistry: structure and binding  
Unmodified DNA/RNA is susceptible to nucleases attack and degradation. Furthermore, 
their poor pharmacokinetics properties (including weak binding to plasma proteins, rapid 
filter by kidney and excretion into urine, and et al) make them undesirable and unacceptable 
therapeutic agents for systemic administration. In order to increase their nuclease stability 
and intrinsic affinity to complementary target RNAs, many efforts have been made to the 
structural modification of DNA or RNA (Kurreck, 2003). Key modifications concentrate on 
the backbone, phosphodiester bond, and sugar ring, giving births to three generations of 
nucleic acid anologs. Representative oligonucleotide derivatives include phosphorothioate 
oligodeoxyribonucleotides (PS-ODNs), 2’-O-methyloligoribonucleotides (2’-OMes), 2’-O-
methoxyethyl oligonucleotides (2’-MOE), locked nucleic acids (LNAs), phosphorodiamidate 
morpholino oligonucleotides (PMOs), thiophosphoroamidate oligonucleotides and peptide 
nucleic acids (PNAs) (Figure 2).  
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Fig. 2. Representative modified antisense oligodeoxyribonuleotides. Replacement in 
structure compared with DNA/RNA is highlighted by dashed rectangle. First generation of 
modified form shown includes only PS-ODNs. Second generation mainly includes 2’-OMes 
and 2’-MOE. Third generation includes a series of DNA/RNA analogs, e.g., LNA, PNA, 
BNA, PMO and thiophosphoroamidate oligonucleotides. 
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Like DNA or RNA, PS-ODNs, LNA and thiophosphoroamidate oligonucleotides are 
negatively charged. Other modified oligonucleotides like PNA and PMO are electric neutral, 
showing little repulsion during hybridization to target DNA or RNA. 2’-OMes, 2’-MOE, 
LNAs, PMOs and PNAs all bind to RNA more tightly than unmodified oligonucleotides or 
PS-ODNs. Therefore, they can be used at shorter lengths and lower concentrations for 
exerting specific and potent RNA silencing effect. Meanwhile, PNA and PMO have 
provided substantially better specificity to the same target sequence than DNA, 
phosphorothioate DNA, and 2’-O-methyl RNA, either at low concentration of 50 nM or at 
high concentration of 3.5 µM (Deere & et al, 2005). Furthermore, it is acknowledged that 
only PS-ODNs activate RNase H to degrade mRNA in eukaryotic cells, whereas the other 
modified oligonucleotides show direct translation arrest effect. The same results have also 
been confirmed for gene manipulation by antisense strategy in bacteria. 
2.2 Antisense antibacterial strategy 
The hypothesis that any gene can be antisense inhibited is quite tantalizing. Therefore, 
antisense oligomers have been studied as bacterial growth inhibitors for developing new 
types of antibiotics. In 1991, Rahman et al firstly observed the inhibited protein synthesis 
and colony formation in normal E. coli by using PEG 1000 attached methylcarbamate DNAs 
targeting the start codon sequence of prokaryotic 16S rRNA (Rahman & et al, 1991). Ever 
since, the potential of gene specific modified AS-ODNs as biomedically useful antibiotics 
has been well accepted and further explored. The present-day antisense antibacterial 
strategy has overcome major obstacles that hampered this innovative approach developing 
into clinically applicable therapeutics: (i) target validation and (ii) efficient delivery system. 
Meanwhile, modified AS-ODNs, e.g. PNA and PMO, have accepted thorough preclinical 
and clinical evaluation on the aspects pharmaceutical properties as promising antisense 
antibiotics. 
2.2.1 Inherent advantages 
Compared to human genome, bacterial genome is much less complicated and homogenous. 
Unlike eukaryotic cells, the double-strand DNA (dsDNA) of bacterial cells locates in 
nucleoid. And in this low electron density zone, there is no nucleic membrane to strictly 
separate biochemical reactions into different time and space level. DNA replication, RNA 
transcription and protein synthesis in bacteria are processed in cytoplasm, which allows 
exogenous AS-ODNs to interfere with genes and/or RNAs more readily. Meanwhile, RNA 
interfering (RNAi) mechanism found in eukaryotic cells has not been reported so far in 
bacteria. Bacteria themselves use antisense as a natural mechanism to inhibit specific gene 
expression, therefore, antisense technology suits better as an effective gene modulating tool 
in bacteria.  
2.2.2 Target identification and validation 
A key objective for discovery of new antisene antimicrobial agents is to determine the genes 
essential for survival of the pathogenic organisms. In paticular, the main critireas for 
measuring the quality of a candidate gene as a good target include vitality of the gene and 
its targeting accessability for antisense oligomers. Compared to gene knockout technique, 
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antisense approach itself has been proved to be an effective tool for target validation in 
bacteria, with controllable sensitivity, larger breadth of applicability and more realistically 
mimic effect of a therapeutic inhibitor (Wright, 2009). 
2.2.2.1 Target site selection and design of AS-ODNs 
Theoretically, antisense antibacterials as modulators of bacterial essential genes can be used 
to alter biological state or behavior in potentially any pathogenic species. Their growth 
inhibitory activity relies on sequence-specific inhibition of gene expression, which offers the 
potential for high specificity in immediate bacteriocidal or bacteriostatic therapeutic 
consequences (Rasmussen & et al, 2007). However, the fundamental requirements for potent 
antisense activity include sufficient concentration of antisense agent at the most sensitive 
targeting site, an ability to hybridize to the target mRNA sequence, the capacity of the 
ODN/mRNA duplex to interfere with gene expression, and sufficient biological stability of 
the antisense agent.  
Antisense inhibitors must bind accessible regions of the target mRNA so that stable 
ODN:RNA(DNA) heteroduplexes or triplex (as for PNA) can be formed to elicit antisense 
effect. In order to obtain the antisense sequence with best potency and efficacy, researchers 
normally follow a comparatively fixed procedure in design (Shao & et al, 2006). Generally, 
possible targeting regions are those nucleotide sequences free of any double strand (e.g. 
hairpin) in secondary structure, which are determined by RNA secondary structure 
softwares (Ding & Lawrence, 2003) within full sequences. Notably, most previous studies 
have demonstrated that the start codon region of the mRNA (see Table 1&2) is the most 
effective region for RNase H independent antisense inhibition, because this region initiates 
the translation and includes the Shine-Dalgarno (SD) sequence (Dryselius & et al, 2003). 
However, a few studies also have confirmed that specific AS-ODNs complementary to sites 
beyond the start codon region receive equal positive results in in vitro efficacy test (e.g. 
antisense targeting of rpoD by PNA in methicillin resistant Staphloccous aureus, Bai & et al, 
2012a). Then, bioinformatic algorithms are used to calculate the DNA: ODN binding 
parameters (e.g. minimal free energy and melting temperature, et al) with setted lengths for 
AS-ODN. According to the combind data, rational analysis was performed to confirm 3-10 
different targeting sites/sequences with highest binding affinity and stability for sequence-
specific antisense inactivation of target genes. AS-ODNs complementary to the chosen target 
sites are synthesized. The length of AS-ODN is predominantly determined by their chemical 
properties. In principle, nucleic acid analogs with stronger affinity to target RNA require 
shorter lengths. Customarily, policy that 14-30 monomers for PS-ODNs and 8-16 monomers 
for PNA, LNA and PMO have been adopted for potent inhibition and achieving better hits. 
In order to improve the uptake of AS-ODNs by the cell, AS-ODNs with attached membrane 
permeabilizing peptides have been developed (elaborated in 2.2.3).  
Presently, in vitro modified minimal inhibitory concentration (MIC) and minimal 
bactericidal inhibitory concentration (MBC) tests of peptide-ODN conjugates are well-
acknowledged methods to preliminarily confirm the antibacterial effect of AS-ODNs. 
Targeted gene vitality and accessability are determined by comparing MIC and MBC 
values. AS-ODN that shows the lowest MIC value indicates the most sensitive targeting 
site for antisense inhibition, whereas the MBC value suggests if the antisense antibacteial 
effect is  bacteriocidal. Target specificity is generally evlauated at the same time by testing 
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the antibacterial activity of designed control AS-ODNs (e.g. AS-ODN with mismacted or 
scrambled nucleotide sequences) and pepides. Further, RT-PCR and western blotting can 
be used to observe the reduction of mRNA and protein product of the particularly 
targeted gene. Collectively, with regard to target selection, researcher are dedicated to 
identify an ideal essential gene that is with small nucleotide content and upmost 
stringency but effective region of coding sequences for potent antisense ihibition (Goh & 
et al, 2009). Meanwhile, the antisene property of AS-ODN itself should also be taken into 
consideration. 
2.2.2.2 Validated targets in bacteria 
2.2.2.2.1 Targeting essential genes 
Essential genes that regulate or control bacterial growth, proliferation, virulence and 
synthesis of important living-dependent substances are candidates attracting the majority of 
research enthusiasms. Validated essential genes among different bacterial species include 
fbpA/ fbpB/fbpC (Harth & et al, 2002, 2007) and glnA1 (Harth & et al, 2000) in Mycobacterium 
tuberculosis, gyrA/ompA in Klebsiella pneumonia (Kurupati & et al, 2007), inhA in 
Mycobacterium smegmatis (Kulyte & et al, 2005), oxyR/ahpC in Mycobacterium avium (Shimizu 
& et al, 2003), NPT/EhErd2 in Entamoeba histolytica (Stock & et al, 2000, 2001), gtfB in 
Streptococcus mutans (Guo & et al, 2006), fmhB/ gyrA/hmrB (Nekhotiaeva & et al, 2004a) and 
fabI (Ji & et al, 2004) in Staphylococcus aureus, 23S rRNA (Xue-Wen & et al, 2007), 16S rRNA 
plus lacZ/bla (Good & Nielsen, 1998), and RNAse P (Gruegelsiepe & et al, 2006) in Escherichia 
coli, and acpP in Burkholderia cepacia (Greenberg & et al, 2010), Escherichia coli (Deere & et al, 
2005b; Geller & et al, 2003a, 2003b, 2005; Mellbye & et al, 2009, 2010; Tan & et al, 2005; Tilley 
& et al, 2007) as well as Salmonella enterica serovar Typhimurium (Mitev & et al, 2009; Tilley & 
et al, 2006). 
 
 
 
Table 1. Continued 
Targeta 
AS-
ODNb
Test 
organismc 
Efficacy identifiedd 
Delivery
Methode 
Reference 
23S 
rRNA 
P.T. center 
PNA 
 E. coli AS19 
(permeable 
membrane) 
in vitro/
IC50 > 20 µM (duplex) 
— Good & Nielsen, 1998  
in vitro/
IC50 = 5 µM (triplex) 
domain II  E. coli Dh5α in vitro/MIC = 10 µM CPP=(KFF)3K Xue-Wen et al,2007  
α-sarcin 
loop 
E. coli AS19 in vitro/IC50 = 2 µM — Good & Nielsen, 1998 
E. coli K12 
(wild-type) 
in vitro/MIC* = 5 µM — 
Good et al, 2001 in vitro/MIC* = 0.7 µM 
CPP=(KFF)3K 
in vitro/MIC = 3 µM 
16S 
rRNA 
preceding 
the start 
codon 
region 
MDNA
 E. coli lacking 
outer cell wall in vitro / inhibit protein 
synthesis and colony 
formation 
—  
Rahman MA et al, 1991 
 normal E. coli PEG attached 
mRNA 
binding site
PNA 
 E. coli AS19 in vitro / IC50 > 20 µM — Good & Nielsen, 1998 
E. coli K12 in vitro/MIC=10 µM CPP=(KFF)3K Hatamoto et al, 2009 
Ref r nces 
ata oto et al, 2010 
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Table 1. Continued 
Targeta AS-ODNb 
Test 
organismc 
Efficacy identifiedd 
Delivery
Methode 
Reference 
acpP  
(start 
codon 
region) 
SD site 
-24 to -13 
nt 
PNA 
  E. coli K12 in vitro / MIC= 1.5 µM  
CPP=(KFF)3K 
Dryselius  et al, 
2003 
-9 to 3 nt 
-5 to 5 nt  
E. coli in vitro / MIC=0.2* or 1 µM Good et al, 2001 
E. coli SM101
(defective 
membrane) 
in vivo/100% rescued mice at a single 
i.p. dose of > 5 nmol 
Tan et al, 2005 
E. coli K12 
in vivo/60% rescued mice at a single 
i.v. dose of 100 nmol 
E. coli K12 
in vivo/ MIC=0.8µM, post antibiotic 
effect duration 11.7h 
Nikravesh  et al , 
2007  
6 to16 nt  
PMO 
E. coli AS19 
in vitro  luciferase system/ 
most potent inhibition 
— Deere  et al , 2005  
 E. coli SM105
(normal 
membrane) 
in vitro / EC = 20µM 
in vivo/sustanied post-infectin 
reduction in cfu at single i.p. dose of 
76 nmol 
— Geller et al, 2005  
E. coli W3110 
(ATCC27325)
in vitro / IC50 CPP1 = 9.5µM 
IC50 CPP2 = 10.8µM 
IC50 CPP3 = 3.6µM 
CPP1=(KFF)3KXB
CPP2=RTRTRFLR
RTXB 
CPP3=(RFF)3XB 
CPP4=(RXX)3B 
Tilley  et al,  2006  EPEC 
(E. coli 
E2348.69)
Ex vivo cocultured Caco-2 culture / 
IC50 CPP2= 5.3µM IC50 CPP3= 0.5µM 
S. enterica 
(ATCC29629)
Ex vivo cocultured Caco-2 culture / 
IC50 CPP2= IC50 CPP3= 0.5µM 
E. coli W3110 
(ATCC27325)
in vivo /100% 48h-after survival in 
mice at i.p. injection of 2 treatments 
with 30µg or 300µg conjugate 
CPP3=(RFF)3XB Tilley et al, 2007  
 
E. coli W3110 
(ATCC27325)
in vitro /MIC from 0.625 to > 80µM 19 synthetic CPPs
Mellbye, 2009 in vivo /100% 48h-after survival in 
mice at i.p. injection of 2 treatments 
with 30µg CPP2-PMO 
CPP1= (RX)6B 
CPP2= (RXR)4XB 
CPP3= (RFR)4XB 
PMO 
S. enterica LT1
in vivo /MIC = 1.25µM 
CPP= (RXR)4XB 
Mitev  et al,, 2009 
3+Pip-PMO
in vivo /MIC = 0.625µM intracellular 
infected macrophage/99% decrease 
in intracellular bacteria at 3µM 
 
Pip-PMO E. coli W3110 
(ATCC27325)
in vivo /MIC3+ = 0.3 µM  
in vivo /100% 48h-after survival in 
mice at i.p. injection of 2 treatments 
with 5 or 15 mg/Kg CPP-PMO 
Mellbye  et al,, 
2010 
Gux-PMO in vivo /MIC5+ = 0.6 µM  
4 to 14 nt 
PMO 
14 B. cepacia 
strains 
 (5 clinical 
isolates+9 
from ATCC) 
in vitro/lowest MIC = 2.5 µM 
CPP= (RFF)4XB 
Greenberg et al, 
2010 -5 to 6 nt 
in vitro/lowest MIC = 2.5 µM in vivo 
/55% 30d-after survival in mice at 
i.p. injection of single dose of  
200 µg CPP-PMO 
References 
Mitev et al, 2009 
ellbye et al,  
CPP1=(RX)6B 
CPP2=(RXR)4XB 
CPP3=(RFR)4XB 
CPP=(RXR)4XB
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Targeta 
AS-
ODNb 
Test 
organismc 
Efficacy identifiedd 
Delivery 
Methode 
Reference 
P15 loop of 
RNase P 
LNA 
 E. coli 
in vitro / bingding affinity value 
only 
— Gruegelsiepe  et al, 
2006 
PNA in vitro/MIC = 5 µM CPP=(KFF)3K
floA 
PNA E. coli AS19 
in vitro/MIC = 2.5 µM 
CPP=(KFF)3K Hatamoto  et al, 2010 
floP in vitro/MIC = 6.5 µM 
glnA1 
PS-ODN
M. tuberculosis
 
in vitro / combination of 3 PS-
ODNs for transcript mRNA, EC 
= 10 µM 
ethambutol or 
polymyxin B 
nonapeptide 
Harth et al, 2000 
fbpA,fbpB, 
fbpC 
in vitro / combination of 4 PS-
ODNs for each transcript 
mRNA, EC = 10 µM 
— Harth et al, 2002  
5'-, 3'-HP 
PS-ODN
in vitro / combination of 3 PS-
ODNs for each transcript 
mRNA, EC = 10 µM 
— Harth et al, 2007 
inhA PNA M. smegmatis in vitro / MIC < 6.5 µM CPP=(KFF)3K Kulyté A  et al, 2005 
adk PNA 
S. aureus
RN4220 
in vitro / MIC = 15 µM CPP=(KFF)3K Hatamoto  et al, 2010 
fmhB 
PNA 
S. aureus 
RN4220 
in vitro / MIC = 10 µM 
CPP=(KFF)3K
Nekhotiaeva et al. 
2004 
gyrA in vitro / MIC = 20 µM 
hmrB in vitro / MIC = 12 µM 
fabI 
UM S. aureus in vitro / MIC = 15 µM — Ji  et al, 2004 
PNA E. coli K12 in vitro/ MIC = 3 µM CPP=(KFF)3K
Hatamoto  et al, 2010 
fabD PNA E. coli K12 in vitro / MIC = 2.5 µM CPP=(KFF)3K
gyrA 
PNA K. pneumoniae
in vitro / MIC = 20 µM 
CPP=(KFF)3K Kurupati et al, 2007 
ompA in vitro / MIC = 40 µM
gtfB PS-ODN S. mutans in vitro / reduce biomass — Guo  et al, 2006  
oxyR/ahpC UM 
M. avium 
complex 
in vitro / ineffective — Shimizu T 2003 
NPT/ 
EhErd2 
UM E. histolytica in vitro / inhibited cell growth — 
Stock  et al, 2001, 
2000   
a The essential genes that were targeted encode the following proteins: acpP, acyl carrier protein; fabI, 
enoyl-acyl carrier protein reductase; fabD, malonyl coenzyme A acyl carrier protein transacylase; folP, 
dihydropteroate synthase; fmhB, protein involved in the attachment of the first glycine to the 
pentaglycine interpeptide; gyrA, DNA gyrase subunit A; hmrB, ortholog of the E. coli acpP gene; adk, 
adenylate kinase; inhA, enoyl-acyl carrier protein reductase; ompA, outer membrane protein A; gtfB, 
synthesis of water-insoluble glucans; inhA, enoyl-(acyl carrier protein) reductase; RNase P, P15 loop of 
RNase P; gyrA, DNA gyrase subunit A; oxyR, oxidative stress regulatory protein; ahpC, alkyl 
hydroperoxide reductase subunit C; glnA1, glutamine synthetase; fbpA,fbpB, fbpC, 30/32-kDa mycolyl 
transferase protein complex; NPT, Neomycin phosphorotransferase; EhErd2, marker of the Golgi 
system; LacZ/bla, beta-galactosidase/beta-lactamase; P.T. indicates peptidyl transferase; SD, Shine-
Dalgarno; nt, nucleotide. 
b UM, unmodfied; MDNA, ethylcarbamate DNA; Pip-PMO and n+Gux-PMO, cations (piperazine or N-(6-
guanidinohexanoyl)piperazine) attached to the phosphorodiamidate linkages; 
c EPEC, enteropathogenic E. coli. 
d Minimal inhibitory concentrations (MIC) were tested in Mueller–Hinton broth, except in case marked 
with an asterisk(*), in which the MIC values were determined in LB broth at 10% of the normal strength; 
IC50 values are the concentrations that caused a 50% inhibition of cell growth relative to control cultures 
that lacked AS-ODN; EC values are the concentrations that caused significant decrease in cell grwoth 
relative to control cultures that lacked AS-ODN; PAE, post antibiotic effect; i.p. indicates intraperitoneal 
and i.v. indicates intravenous. 
e CPP, cell penetrating peptide; PEG, Polyethylene glycol; “—”, no delivery method used. For synthetic 
peptides, X is 6-aminohexanoic acid and B is beta-alanine. 
Table 1. Examples of AS-ODNs targeting essential genes in antibacterial therapy. 
References 
i izu T,  
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2.2.2.2.2 Targeting resistance mechanism 
Developing resistance inhibitors in traditional antibiotic industry is a sound, well-validated 
strategy for tackling resistance problems, because they postpone the “expire date” of on-
market antibiotcs and expand their application. The economic and clinical value of this 
rationale is well recognized and demonstrated by offering new combinations to clincal 
practice. Thus, a few studies focused on interrupting the expression of genes involved in 
resistant mechanism by antisense approach, aiming to restore bacterial susceptibility to key 
antibiotics in clinical practice.  
 
 
Target Encoding Proteins 
AS-
ODNa 
Test 
organism 
Efficacy 
identified 
Delivery
Methodb
Reference 
oprM 
outer membrane efflux 
protein 
PS-ODN P. aeruginosa in vitro liposome Wang et al, 2010 
mecA 
penicillin-binding 
protein 2 prime 
PS-ODN S. aureus in vitro & in vivo liposome
Meng J et al, 2006, 
2009 
cmeA 
CmeABC multidrug 
efflux transporter 
PNA C. jejun in vitro CPP Jeon B et al, 2009 
aac(6’)-
Ib 
aminoglycoside 6'-N-
acetyltransferase type 
Ib, mediate amikacin 
resistance 
UM  E. coli 
EGS mediated 
RNaseP leavage
/ in vitro 
— 
Soler Bistué AJ et al, 
2007 
in vitro EP Sarno R et al, 2003 
metS/ 
murB 
methionyl-tRNA 
synthetase /UDP-N-
acetylenolpyruvoylgluc
osamine reductase 
UM B. anthracis in vitro — Kedar GC et al, 2007 
act 
chloromycetin acetyl 
transferase 
UM  E. coli 
EGS mediated 
RNaseP leavage
/ in vitro 
— Gao MY et al, 2005 
in vitro — Chen H et al, 1997 
vanA 
class A (VanA) 
glycopeptide- 
resistant related protein
UM E. faecalis  in vitro — Torres VC et al, 2001 
marOR
AB 
multiple antibiotic 
resistance operon 
PS-ODN  E. coli in vitro HS/EP White DG et al, 1997 
LacZ/bla 
β-galactosidaze/  
β- l actamase PNA 
E. coli AS19
(permeable 
membrane) 
in vitro — Good & Nielsen, 1997 
 
a  UM, unmodfied. 
b CPP, cell penetrating peptide; EP, electroporation; HS, heat shock; EGS, external guide sequences; “—
”, no delivery method used. 
Table 2. Examples of AS-ODNs targeting resistance mechanism in antibacterial therapy. 
First proof-of-principle evidence was given by White et al in 1997 for successful increasing 
the bactericidal activity of norfloxacin by antisense inhibiting the marRAB operon  
in Escherichia coli (White & et al, 1997). Hitherto, limited but successful trials have 
extended to dominating resistant genes and bacterial species with highest incidence of 
resistance (Table 2), e.g., antisense targeting aac(6')-Ib (Sarno & et al, 2003; Soler Bistue & 
et al, 2007), act (Chen & et al, 1997; Gao & et al, 2005) in Escherichia coli, vanA in 
Enterococcus faecalis (Torres & et al, 2001), cmeA in Campylobacter jejun (Jeon & Zhang, 
2009), mecA in Staphylococcus aureus (Meng & et al, 2006; Meng & et al, 2009), metS/murB in 
Bacillus anthracis (Kedar & et al, 2007) and oprM in Pseudomonas aeruginossa (Wang & et al, 
2010).  
References 
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2.2.3 Efficient delivery systems 
Virtually, any microbial gene could be targeted and highly organism-specific drugs could be 
envisioned in the development of antisense therapeutic agents. The obvious obstacle is 
stringent bacterial cell membrane for penetration or poor cellular uptake of AS-ODNs. An 
unmodified 10-mer oligonucleotide is 2-3 kDa, and various chemical modifications outlined 
above add further to this size. In short, AS-ODNs are likely to be considerably larger than 
vancomycin, therefore require efficient delivery systems. A variety of strategies exist to 
deliver compounds to bacterial cells in the laboratory, including electroporation, 
permeablilizing solvents, cationic lipid formulations (e.g. liposome), and pore-forming 
peptides (see Table 1&2). Although what exactly will work for AS-ODNs remains to be 
determined, the cell penetrating peptide (CPP) mediated delivery of AS-ODNs (especially 
peptide-PNA and peptide-PMO conjugates) outperformed other delivery systems in way of 
reaching future therapeutic applications. 
2.2.3.1 Limitation in cellular uptake 
Many barriers exist for the efficient transfer of genes/oligonucleotide anologs into cells, 
including the extracellular matrix, the endosomal/lysosomal environment, the endosomal 
membrane, and the nuclear envelope. Many delivery systems have been proved to serve 
suitably for antisense approach in eukaryotic cells regardless of their types (non-viral or 
viral) vs cell types. However, like most oligonucleotide-based strategies, the major limitation 
of antisense antibacterials is their poor cellular uptake due to low permeability of bacterial 
cell membrane to modified nucleic acids (Nekhotiaeva & et al, 2004). In particular, 
lipopolysaccharide outer membrane of gram-negative bacteria is a major barrier to molecule 
uptake (Good & et al, 2000). Meanwhile, decreased membrane permeability has been 
permanently observed for originally antibiotic-susceptible bacterial species after frequent 
exposure to multiple antibiotics present in commensal environments. Alternatively, 
membrane-associated energy-driven efflux in bacteria is of extremely broad substrate 
specificity, preventing intracellular drugs to release sustained effects. 
2.2.3.2 Cell penetrating peptide (CPP) mediated delivery 
Further, antisense antibacteirals may require development of delivery conditions for each 
bacterial species. Several strategies have been developed to improve delivery of 
oligonucleotides both in cultured cells and in vivo. So far, there is no universally applicable 
method for their delivery into different gram-positive and gram-negative specie, as they all 
present several limitations. Peptide-based strategies, representing a new and innovative 
concept to bypass the problem of bioavailability, have been demonstrated to improve the 
cellular uptake of nucleic acids both in cultured cells and in vivo.  
Cell-penetrating peptides (CPPs) are short peptides of less than 30 amino acids that are able 
to penetrate cell membranes and translocate different cargoes into cells. The only common 
feature of these peptides appears to be that they are amphipathic and net positively charged. 
CPPs constitute very promising tools and have been successfully applied in vivo (Crombez 
& et al, 2008; Morris & et al, 2008). Two CPP strategies have been described to date; the first 
one requires chemical linkage between the drug and the carrier peptide for cellular drug 
internalization, and the second is based on the formation of stable complexes with drugs, 
depending on their chemical nature. Recently, the second strategy has the tendency to 
replace the first strategy for convenient delivery of DNA or AS-ODNs into eukaryotic cells, 
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especially considering the synthesis and cost issues. However, CPP-conjugated method is 
now extensively applied for antisense antimicrobial ODNs. 
In order to improve cellular uptake of PNA into bacterial cells, Good L and Nielsen PE, who 
first established CPP conjugating to the end of PNA in chemical synthesis, have realized 
efficient delivery of PNA through bacterial out membrane by observing its potent 
bacteriocidal antisense effects at micromolar ratio (Eriksson & et al, 2002). Further evidence 
demonstrates that introducing spacers or linkers between PNA and CPP in the direct 
covalent conjugate may increase its antisense efficacy and antibacterial potency. It also has 
been demonstrated that the release property of the chemical bond between PNA and CPP 
(e.g. the more stable amide bond or the less stable disulfide bond) has no influence on the 
antisense efficacy of PNAs. Later chemistry inventions make possible the conjugation CPP 
to other oligonucleotide analogs (e.g., PS-ODNs, LNAs, PMOs) for imparting them into 
bacterial cells and specific intracellular targets.  
Regarding CPP itself, the mechanism of cell wall penetration is controversial and still under 
exploration.  Nonetheless, the improvement in bacterial uptake of AS-ODNs with the aid of 
CPP has been well-recognized, making it an indispensable delivery system before no 
advanced system is developed (Lebleu & et al, 2008). The “carrier peptide” KFFKFFKFFK, 
originally reported for efficient penetrating ability through brain blood barrier, is the first 
also the most extensively applied peptide sequence verified by Nielsen PE and Good L et al 
for successful delivery of PNA into Escherichia coli. Previous studies suggested that the 
repeated amphipathic motif with cationic residues followed by hydrophobic regions is an 
important structure for carrier efficiency of CPP. The more efficient peptide sequences 
RFFRFFRFFRXB and RXRRXRRXRRXRXB (X is 6-aminohexanoic acid and B is β-alanine), 
have been recently reported for improved delivery efficacy of CPP-attached PMOs. Many 
efficient and simple penetrating efficacy test models for CPPs have been established in 
eukaryotic cells, whereas standard qualification method has been developed for only a few 
bacterial species. Evidence shows that the efficacy of CPPs differs according to bacterial 
species, and the underlying mechanisms are still unclear. Inadequate information has been 
accumulated from sporadic studies, e.g., (KFF)3K facilitates delivery of PNAs and PMOs 
into Escherichia coli, Salmonella enterica serovar Typhimurium, Klebsiella pneumoniae (however 
much less potent) and Staphylococcus aureus. But it is not working for Pseudomonas aeruginosa 
membrane even at higher concentrations of conjugated PNAs. (RFF)3RXB and (RXR)4XB 
enables more efficient transporting of PNAs and PMOs across the membrane of Escherichia 
coli, Salmonella enterica serovar Typhimurium, Klebsiella pneumonia, Staphylococcus aureus and 
Pseudomonas aeruginosa. Notably, the membrane of two gram-negative species Acinetobacter 
baumanni and Shigella flexneri show highest sensitivity to (RXR)4XB mediated PNA-CPP 
conjugates (unpublished results, and Bai & et al, 2012b). Following studies demonstrated 
that gram positive bacteria Bacillus subtilis and Corynebacterium efficiens exhibit increased 
susceptibility to CPP-PNAs, but in contrast, the gram-negative bacterium Ralstonia 
eutropha was not affected by addition of CPP-PNA.  
2.2.3.3 Nano-material based delivery system  
Nanomedicine is a growing field with a great potential for introducing new generation of 
targeted and personalized drugs. Membranes of eukaryotic cells and organelles, as well as 
the cell wall and membrane of pathogenic microorganisms, constitute a serious barrier for 
 
Antisense Antibacterials: From Proof-Of-Concept to Therapeutic Perspectives 
 
331 
the access of hydrophilic drugs to their target molecules inside the cell structures. To 
overcome gene delivery problems of macro-molecule like AS-ODNs, various nano-mateiral 
based delivery techniques, including linear polymers, dendrimers and carbon nano tubes, 
have been developed and further studied as delivery tool for gene therapy purposes. And 
some of them are definitely worthy of extended trials in the antisense antibacterial aspect, 
with regard to delivery efficiency and other important pharmaceutical properties (e.g. 3D 
size, large scale synthesis and chemical modification, solubility, bioavailability, 
biocompatibility, toxicity, and pharmacokinetics, et al). 
2.2.3.3.1 Dendrimers as vectors 
Dendrimers are new class of synthetic polymeric materials characterized by well-defined 
and extensively branched 3D structure (Figure 3A). They have narrow polydispersity, 
nanometer size range, which can allow easier passage across biological barriers (e.g. small 
enough to undergo extravasations through vascular endothelial tissues). Notably, affordable 
commercialization of different types of size-controllable and surface-functionalized 
dendrimers is now available, providing a high degree of versatility. Besides,  the unique 
properties of funtinonalized dendrimers, such as uniform size, high degree of branching, 
water solubility, multivalency, well-defined molecular weight and available internal 
cavities, have made them promising biological and drug-delivery systems for traditional 
drug (i.e. classical organic types) and gene therapy (e.g. DNA, small interfering RNAs, AS-
ODNs,  IgG antibodies, etc.) applications (Ravina & et al, 2010). And their excellent 
pharmacological properties, such as cytotoxicity, bacteriocidal and virucidal effect, 
biodistribution and biopermeability, may be modulated to fit  specific medicinal purposes.  
The wide range of applications reported for the use of dendrimers as delivery vectors for 
versatile cargos in the patent and literature demonstrates the general applicability of these 
molecules as carrier candidate for antisense antibacterials. There have been reports on the 
use of poly(amidomide) based dendrimers (e.g. PAMAM) for the development of 
antibacterial drugs mainly by destroying the cell walls of pathogenic organisms with their 
cationic surface groups, leading to direct cell death. However, our research suggests that 
lower generation of polyamide dendrimers, such as G1.0 and G2.0 PAMAM, showed no 
cell-wall impairment to many bacterial species (unpublished data, Xue et al, 2010), 
becoming a highly active vector for bacteria-specific oligonucleotides. Thus, dendrimers are 
highly suitable tools in antisense drug discovery to a wide variety of bacterial receptors.  
Branching units
Core mioety
Void spaces
Surface groups
              
Fig. 3. (A) Schematic representation of generation 4 (G4.0) dendrimer. (B) Molecular 
structures of a multi-walled carbon nanotube (MWNT). 
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2.2.3.3.2 Funtionalized multi-walled carbon nanotubes (MWCNTs) as vectors 
Synthetic inorganic gene nanocarriers have received limited attention in the transformation 
of bacterial cells. Amongst new generation of nano-vectors are carbon nanotubes (CNTs), a 
new form of carbon made-up of graphene layers rolled-up into a cylindrical from which can 
be produced as single or multi-walled (Figure 3B). The physico-chemical features of CNTs, 
such as needle-like shape, nanorange size, surface modification flexibility, and electronic 
properties, make them unique materials in nanoscience and nanotechnology. Multi-walled 
carbon nanotubes (MWCNTs) can be fabricated as biocompatible nanostructures (cylindrical 
bulky tubes), forming supramolecular complexes with proteins, polysaccharides and nucleic 
acids (Kateb & et al, 2010). These structures have been under investigation in the biomedical 
domain and in nanomedicine as viable and safe nanovectors for gene and drug delivery.  
Research work based on nanobiotechnologies has allowed us to develop complex antigenic 
systems and novel delivery routes for peptides, nucleic acids and drugs covalently linked or 
simply adsorbed onto carbon nanotubes. In particular, Rojas-Chapana J and et al have 
presented a plasmid delivery system based on water dispersible multi-walled carbon 
nanotubes (CNTs) that can simultaneously target the bacterial surface and deliver the 
plasmids into E. coli cells via temporary nanochannels across the cell envelope (Rojas-
Chapana & et al, 2005). It is the first experimental evidence that shows high potential of 
CNTs for nanoscale cell electroporation in bacteria. However, the study of metabolism, the 
toxicity and the mechanism of elimination of water-soluble carbon nanotubes in order to 
evaluate their impact on the health and validate the concept of CNT as new delivery system 
still arouse concerns in many critial ways. Recently initiated researches on hybriding the 
dendrimers with MWCNT has offered us new hopes (Qin & et al, 2011; Zhang & et al, 2011). 
Besides increased dispersility, solubility, biocompatiability and stability, (MWCNTs)-
polyamidoamine (PAMAM) hybrid prepared by covalent linkage has possessed good 
plasmid DNA immobilization ability and efficiently delivered GFP gene into cultured HeLa 
cells. The surface modification of MWCNTs with PAMAM improved the transfection 
efficiency and simultaneously decreased cytotoxicity by about 38%, as compared with 
mixed acid-treated MWCNTs and pure PAMAM dendrimers. The MWCNT-PAMAM 
hybrid can be considered as a new carrier for the delivery of biomolecules into both 
mammalian and bacterial cells.  
2.2.4 Other pharmaceutical properties 
As far as the other properties in therapeutic application of antisense antibacterials are 
concerned, there should always be a systematic overview of cargo (i.e. oligonucleotides) and 
vector (especially the CPP, Heitz & et al, 2009). With regard to AS-ODNs, the electric neutral 
PNA and PMO calsses emerge and show desirable properties (especially their non-ionic 
backbones) as better therapeutic alternative to other antisense agents. And with regard to 
delivery strategies, alternative nonviral methods, such as electroporation and the use of 
liposomes, have been developed for delivery of antibacterial AS-ODNs. These methods have 
been proved to be effective in vitro and for research purposes, but showed limited potential 
for delivery in vivo due to toxicity, cell damage, and immunogenicity. They are also 
technically demanding in their application, lack tissue and cell specificity, and can deliver 
material to only a limited amount of cells. In view of these considerations, peptide 
conjugated AS-ODNs (i.e. peptide-PNAs and peptide-PMOs) offer a promising noninvasive 
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version of gene scilencers with potent antisense antibacterial activity, the pharmaceutical 
properties of which this part will mainly focus on. 
2.2.4.1 PNAs, PMOs and their peptide conjugates 
PNAs and PMOs (also known as morpholino) are novel classes of antisense agents that offer 
a better therapeutic alternative to other antisense antibacterial oligomers. They both possess 
a non-ionic backbone, but differed in ribose sugar replacement. For PMO, the backbone of 
DNA is replaced by a 6-membered morpholine moiety and the phosphorodiester 
intersubunit bonds with phosphorodiamidate linkages. PNA has a pseudopeptide backbone 
composed of (2-aminoethyl)glycine units, in which the geometry and the spacing of the 
bases is nearly identical to that found in a native DNA or RNA strand. The polyamide 
backbone of PNA has no phosphate groups, having an amino (NH2) to carboxyl (CO2H) 
orientation instead of 5' to 3' orientation as do phosphodiester backbones. Specifically, PNAs 
can bind to either single-stranded DNA or RNA, in which the resulting hybrid resembles the 
B-form of DNA, or double-stranded DNA, in which the PNA invades the DNA double 
stranded helix and hybridizes to the target sequence, thus displacing the second DNA 
strand into a ‘D’loop. Although departing significantly from the sugar-phosphate backbone 
found in regular DNA, oligomers of both types independently (i.e. with or without delivery 
strategies) have been found to be remarkable steric-block ODNs for inhibiting translation 
and blocking mRNA activity, as demonstrated in embryos, cells and animals. Now PMOs 
have been taken to pre-clinical studies for treatment of cardiovascular diseases, viral 
diseases and genetic disorders, such as Duchenne muscular dystrophy (DMD). 
Since the conjugation of CPP to negatively charged ODNs (e.g. PS-ODNs) did not result in a 
level of delivery into cells sufficient for biological activity, PNA- and PMO- CPP conjugates 
(covalently linked with or without spacers) confer on these compounds more desirable 
properties over the original ODN forms, as well as ribozyme and siRNA counterparts 
(Thompson & Patel, 2009), especially with respect to antisense antibacterials. Several CPPs 
have been developed for bacterial-specific transformation purposes (as mentioned in 
2.2.3.2), and they can be coupled to PNA or PMO by flexible linker types (Venkatesan & 
Kim, 2006). No general rules have yet emerged as to optimal linkage types, since the factors 
affecting biological activity are often complex. Early popular labile linkers for PNA and CPP 
include AEEA (8-amino-3,5-dioxo-octanoic acid, a polyether spacer also known as an O-
linker), and disulfide bond linkage, which were proposed to be cleavable within the 
reducing environment of the cell. Stable linkage such as glycine linkage, thioether linkage 
and thiol-maleimide linkage have also been reported for improved in vivo stability. The 
conjugation of CPPs and PMOs through a thioether (maleimide), disulfide or amide linker 
have previously been described. The nuclear antisense activities of the CPP–PMOs with the 
three linkage types were similar (Lebleu & et al, 2008). But, the amide linkage is 
advantageous with regard to synthetic procedures (e.g. greater yield and less steps) and in 
vivo stability.  
2.2.4.2 Tissue distribution, pharmacokinetics and stability  
The modified chemistry of PNAs and PMOs provides excellent resistance to nuclease and 
protease activity, which is the basis for the enhanced stability in plasma, tissues, 
cerebrospinal fluid and urine. Independently, the non-ionic character of the PNA/PMO 
portion of the conjugates avoids potential non-specific drug interactions with bacteiral 
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cellular components (except for the target RNA sequence) observed with PS-ODNs. In 
addition, the neutral character of PNAs and PMO chemistry not only guarantees a high 
safety profile but also sufficient tissue concentrations required for effective PNA or PMO 
oligonucleotide:RNA duplex formation, thus enhancing their affinity for the target RNA 
sequence and hence increasing efficacy. Rational design of conjugates (i.e. the optimal linker 
type and position of CPP) may eliminate CPP’s stereospecific blockade that might 
significantly influence the antisense effect of PNA or PMO in target recognization, base 
matching and binging affinity. However, stability of CPPs coupled to antisense PNA or 
PMO may be a matter of concern. This is partially due to the fact that degradation of CPP in 
solution and plasma has been observed for systematic delivery of CPP-2’MOE in mouse 
model (Henke & et al, 2008). Another concern is the non-specificity of CPP mediated 
delivery of PNA or PMO when eukaryotic cells and prokaryotic cells exist in commensal 
environment. Although little lethal damage to cells would be done by conjugated CPP at 
equal molar ratio of PNA or PMO used at the highest concentrations in vitro and ex vivo, the 
consequences of its non-specific physical disruption to normal human cell membranes in 
vivo have not been thoroughly evaluated. Systematic study on CPP mediated antisense 
antibacterial therapy needs to be done if any possible candidate for clinical development is 
ever recommended (Zorko & Langel, 2005). 
The application of unmodified PNAs as antisense therapeutics has been limited by their low 
solubility under physiological conditions, insufficient cellular uptake, and poor 
biodistribution due to rapid plasma clearance and excretion. The excelent stability of PNA-
CPP conjugates has been confirmed for a 48h period at 37℃ in rat’s plasma (Bai & et al, 
2012b). However, there has been no report of in vivo tissue distribution and 
pharmacokinetics properties of CPP-PNA conjugates targeting bacterial genes. Nontheless, 
limited information from PNA-CPP conjugates targeting genes in eukaryotic cells can be 
refered. Jia et al have determined that PNA-CPP conjugates targeting bcl-2 mRNA showed 
specific tumor uptake, low uptake in blood and organs (e.g. liver and slpeen) except for 
kidney, as well as slower urinary clearance in Mec-1–bearing severe combined 
immunodeficiency (SCID) mice. Recently, Wancewicz et al have reported that conjugation of 
PNA (targeting murine phosphatase and tensin homolog) to short basic peptides (serve as 
solubility enhancers and delivery vehicles) allowed for rapidly distribution and 
accumulation of conjugates in liver, kidney and adipose tissue, while their rates of 
elimination via excretion were dramatically reduced compared to unmodified PNA. 
Unlike CPP-PNA conjugates, the pharmaceutical properties of CPP-PMO conjugates have 
been evaluated in an extensive scope besides specific gene modulators (Amantana & et al, 
2007). In general, the conjugation of CPP to PMO enhances the PMO pharmacokinetic 
profile, tissue uptake, and subsequent retention. Amantana et al have reported that 
conjugation of a PMO to the (RXR)4XB peptide increased the tissue uptake (in all organs 
except in brain, with greater increase being seen in liver, spleen and lungs) and retention 
time in these organs, while efflux of the conjugated PMO from tissues to the vascular space 
was slow. They have also confirmed that peptide conjugation also improved the kinetic 
behaviour of PMO as demonstrated by increased volume of distribution, estimated 
elimination half life, and area under the plasma concentration versus time curve. 
Youngblood et al have determined that the stabilities of CPP–PMO conjugates in cells and in 
human serum varied according to CPP sequences, amino acid compositions and/or linkers. 
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The stability of a (RXR)4XB peptide in the conjugate exhibited time- and tissue-dependent 
degradation, with biological stability ranked in the order of liver＞heart＞kidney＞plasma. 
Meanwhile, the PMO portion of the conjugates was completely stable in cells, serum, 
plasma and tissues. 
2.2.4.3 Toxicity 
Large amount of data concerning toxicity of CPP-PNA conjugates have been collected from 
ex vivo studies (Alksne & Projan, 2000; Kurupati & et al, 2007), in which antisense peptide-
PNAs cured cell cultures that were infected with bacteria in a dose-dependent manner 
without any noticeable toxicity to the human cells. In vivo inhibition of gene expression and 
growth have been observed for anti-acpP CPP-PNA conjugates in mouse intraperitoneal E. 
coli infection. However, none toxicity issues have yet been seriously addressed. 
CPP-PMO conjugates targeting bacterial essential genes have been evaluated to confirm 
their bacteriocidal antisense effect in several animal bacteremia models, and have proven 
to be efficacious with an excellent safety profile (Amantana & et al, 2007) within doeses 
for 100% survival 48h after treatment.  They have also found that survival was 
significantly reduced for mice treated with 2×300 mg and 2×1 mg of the 11-base  
AcpP peptide-PMO, indicating toxicity at these high doses. Generally, the toxicity of 
(RXR)4XB -PMOs is caused by (RXR)4XB while the PMO portions of the conjugates are 
essentially non-toxic. In particular, data from CPP-PMO conjugates targeting genes in 
eukaryotic cells have demonstrated that the degree of toxicity depends on the dose, dose 
frequency and route of administration. Collectively, mice tolerated (RXR)4XB-PMOs well 
with repeated intraperitoneal (i.p.) or intravenous (i.v.) injection doses of ≤15 mg/kg at 
diverse time intervals, showing no changes in behaviour, weight and serum chemistry, 
and no histopathological abnormalities were detected in major organs. However, at 
higher doses and dosing frequency, animals experienced weight loss, despite maintaining 
their normal organ weights and appearances. Rats treated with a single 150 mg/kg dose 
appeared lethargic immediately after the injection and proceeded to lose weight, 
accompanied by affected kidney function. The LD50 of a (RXR)4XB-PMO in rats was 
around 220–250 mg/kg. 
3. Broad-spectrum antisense antibacterials 
A range of functional genes in bacteria have been validated as potential targets by using 
unmodified PNAs or CPP conjugated ODNs. Collectively, consistent efforts on antisense 
targeting of a small bacterial gene acpP  (encoding the essential fatty acid biosynthesis 
protein) have passed the proof-of-principle phase and have gathered plenty of positive 
results, especially from recent studies focusing on in vivo confirmation of anti-rpoD peptide-
PMO’s bactericidal effect in mice infected with several pathogenic bacteria (i.e., Escherichia 
coli, Salmonella enterica serovar Typhimurium, and Burkholderia cepacia. However, few reports 
describe promising gene targets that have potential for broad-spectrum antisense growth 
inhibition among different bacterial species. Indeed, the validated targets in different 
bacterial species show discouragingly low similarity in gene sequence and homology. Thus, 
identification of gene targets for broad-spectrum antisense inhibition would aid the 
development of new antimicrobial agents that could relieve the exacerbating therapeutic 
consequences caused by MDR/PDR infections.  
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3.1 Target accessibility  
A challenging aspect of identifying essential genes in bacteria for broad-sepctrum antisense 
inhibition mainly involves efforts to locate the exact targeting site within a specific gene for 
realization of the most potent and specific antisense inhibitory effect of complementary AS-
ODNs against different species (e.g. among gram-negatives, gram-positives, or both). 
Naturally, prequisities in target selection require searching for genes with high similarity 
and identidy amongst as many bacterial species as possible. As time comsuming as it is, an 
economical way of identifying genes that acturally fit this critea should focus on the 
validated targets for both traditional antibiotics and antisense antibacteirals, certainly 
because massive open data of their gene sequencing are available. 
Antisense suppression of the above mentioned essential genes (e.g. 16S rRNA, acpP, gyr, and 
et al) in single bacterial species has showed potent growth inhibitory and cell death effect in 
a sequence-specific and dose-dependent manner. However, the issue of target accessability 
among different species still needs investigation and validation. (1) The ribosome has a 
complex structure involving rRNAs and ribosomal proteins, and therefore, inaccessibility of 
the target site could be one of the reasons for the ineffectiveness of the antiribosomal ODN. 
(2) Systematic researches in vitro and in animal models have demonstrated that one 
potential target acpP (encoding acyl carrier protein AcpP) opens limitless possibility for 
recommending the very first “antisense antibiotic” into market. Besides, acpP gene in 
pathogenic gram-negative species share highly homology in sequences, making itself an 
ideal candidate for antisense antibacterials with broad anti-gram-negative spectrum, 
although more candidate bacterial species are needed to confirm the accessibility of an 
already-validated 11-nucleotide targeting site in its start codon region of mRNA. (3) 
Meanwhile, newly discovered gene targets for new types of protein-targeting antibiotics, i.e. 
the bacterial cell division inhibitor (targeting bacterial cell division protein FtsZ for 
terminating bacterial proliferation (Boberek & et al, 2010)) and virulence inhibitor (targeting 
quorum sensing sensor protein QseC without affecting bacterial growth (Alksne & Projan, 
2000)), also show promises and potential for developing specific or broad-spectrum 
antisense antibacterials based on their homology assessment. (4) our researches focus on 
validating the known target in broad-spectrum antibiotic development by antisene strategy, 
in which the DNA-dependent RNA polymerase (RNAP) is a candidate of great interest for it 
distinct advantanges (see 3.3). 
3.2 Universally applicable delivery systems 
Furthermore, the term “broad-spectrum“ also qualifies the delivery systems for AS-ODNs. 
Specifically, rational design of peptide-ODN conjugates could optimize the effective AS-
DONs in way of enhancing antibacterial potency and expanding antibacterial spectrum, in 
which CPP choice is of equal importance. The range of sensitivities observed for different 
bacterial species to CPPs largely determines their application potential. To our knowledge, 
the synthetic CPP (RXR)4XB has shown by far the most broad cell pernetrating range as an 
effective tool for intracellular AS-ODN delivery into many major gram-negative and gram-
positive pathogens. And the transfection efficiency of the widely used CPPs (RXR)4XB and 
(KFF)3K appears to reflect with the features of bacterial cell walls of clinical isolates, where 
less potent effects were observed for (KFF)3K against species with stringent cell barrier (e.g., 
Klebsiella pneumoniae and Pseudomonas aeruginosa). Collectively, our results suggested that 
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the peptide component of peptide-PNA conjugates may be developed for a wide range of 
indications to realize broad antisense antibacterial spectrum.  
3.3 proof-of principle studies 
Bacterial DNA-dependent RNA polymerase (RNAP) is a key enzyme in transcription 
regulation and gene expression. Its function requires coordination of a core enzyme 
(comprising five subunits α2, β, β’ and ω) and an independent σ subunit that is reversibly 
recruited by core enzyme. The RNAP core enzyme is responsible for transcription 
elongation, and different σs are in charge of transcription initiations from promoters that 
express genes in diverse function. Deactivation of RNAP by any possible means leads to 
direct cell death, attracting much exploration for developing specific RNAP inhibitors, the 
most representative class of broad-spectrum antibiotics (e.g. the rifamycins) with 
fundamental clinical significance. The most developed σ70 family of σs, especially the 
primary σ70, is essential for initiating transcription of multiple genes in exponentially growth 
cells , which to our knowledge has not previously been demonstrated for target validation. 
And most importantly, gene rpoD (encoding the primary σ70 of RNAP) is highly conserved 
in identity and homologous in sequence among different pathogenic gram-negative species. 
Such features are distinct advantages for developing broad-spectrum antisense antibacterial 
agents (Bai & et al, 2011).  
Results from our lab (unpublished and Bai & et al, 2012b) gives the first proof-of-principle 
evidence for exploring and identifying bacterial RNAP σ70 as an antibacterial target by 
antisense strategy. We identified a conserved target sequence within the native rpoD mRNA 
start codon region, and a cell penetrating peptide (RXR)4XB conjugated 10-mer peptide 
nucleic acid was developed for potent sequence-selective bacteriocidal antisense effect 
against six pathogenic gram-negative species, including Escherichia coli, Salmonella enterica, 
Klebsiella pneumoniae, Shigella flexneri, Citrobacter freundii, and Enterobacter cloacae. It cured 
endothelial cell cultures from lethal infection with single or triple GNB without showing any 
apparent toxicity. It specifically interferes with rpoD mRNA, and inhibited the expression of 
σ70 in a concentration-dependent manner. Its in vivo antibacterial activity has also been 
confirmed by increased survival in bacterial infected mice.  
4. Conclusion  
New classes of antisense antibacterial agents (bactericidal agents or resistance inhibitors), 
represent an evolutionary inevitability in antibiotic industry. In the past 20 years, many 
essential genes have been studied as potential targets for developing bactericidal antisense 
agents or resistance inhibitors against clinically pathogenic bacteria. Nonetheless, much 
investment needs to be infused for converting this concept into real drugs. Identified targets 
with application potentiality or new targets under investigation should be further evaluated 
for posing the least risk for selection of resistant variants. Nucleic acid monomers with 
simple synthesis and cheap source of starting materials are more viable as antisense drugs. 
Versatile of delivery systems developed for eukaryotic cells, e.g., polymers, dendrimers, 
nanotubes, should be given considerations for AS-ODNs delivery in bacteria, if no more 
innovative systems than the non-invasive CPP-mediated delivery system is created. 
Furthermore, it is more practical and economical to develop antisense agent that targets 
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only multiple-resistant or pan-resistant bacteria, particularly when it allows co-
administration of a narrow-spectrum antibiotic. Most importantly, “broad-spectrum” 
antisense antimicrobials should also be developed to meet future clinical requirements, in 
which target selection and validation address more attention. 
We have already lagged behind our therapeutic initiatives to meet the challenges of 
increasing isolation of new antibiotic-resistant bacterial strains. A great many functional 
genes discovered in the past decade represent themselves as potential targets for developing 
antibacterial therapeutic agents with whole new mechanisms. Thus, innovative approaches 
must become a priority in antibitoitc discovery, in which antisense antibacterial strategy is 
absolutely a leap in our ability to effectively treat human pathogens of great concern 
(Woodford & Wareham, 2009). The theoretical advantage of antisense antibacterials is 
obvious and has been well-acknowledged by strong evidence in the long process of 
conquering major technological obstacles. It is our continous efforts that will make ultimate 
success in this glorious field. 
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